149 related articles for article (PubMed ID: 35567649)
1. Germline sequencing for presumed germline pathogenic variants via tumor-only comprehensive genomic profiling.
Kondo T; Yamamoto Y; Fukuyama K; Kanai M; Yamada A; Matsubara J; Quy PN; Yoshioka M; Yamada T; Minamiguchi S; Matsumoto S; Kosugi S; Muto M
Int J Clin Oncol; 2022 Aug; 27(8):1256-1263. PubMed ID: 35567649
[TBL] [Abstract][Full Text] [Related]
2. Handling of Germline Findings in Clinical Comprehensive Cancer Genomic Profiling.
Okazawa-Sakai M; Yamamoto Y; Futagawa M; Okamura M; Miyawaki S; Nishina T; Takehara K; Kozuki T; Tomida S; Hyodo I; Ohsumi S; Hirasawa A
Acta Med Okayama; 2022 Dec; 76(6):673-678. PubMed ID: 36549769
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of pathogenic germline variants in the circulating tumor DNA testing.
Yamamoto Y; Fukuyama K; Kanai M; Kondo T; Yoshioka M; Kou T; Quy PN; Kimura-Tsuchiya R; Yamada T; Matsumoto S; Kosugi S; Muto M
Int J Clin Oncol; 2022 Oct; 27(10):1554-1561. PubMed ID: 35870019
[TBL] [Abstract][Full Text] [Related]
4. Management of patients with presumed germline pathogenic variant from tumor-only genomic sequencing: A retrospective analysis at a single facility.
Kawamura M; Shirota H; Niihori T; Komine K; Takahashi M; Takahashi S; Miyauchi E; Niizuma H; Kikuchi A; Tada H; Shimada M; Kawamorita N; Kanamori M; Sugiyama I; Tsubata M; Ichikawa H; Yasuda J; Furukawa T; Aoki Y; Ishioka C
J Hum Genet; 2023 Jun; 68(6):399-408. PubMed ID: 36804482
[TBL] [Abstract][Full Text] [Related]
5. Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort.
Vanni I; Pastorino L; Andreotti V; Comandini D; Fornarini G; Grassi M; Puccini A; Tanda ET; Pastorino A; Martelli V; Mastracci L; Grillo F; Cabiddu F; Guadagno A; Coco S; Allavena E; Barbero F; Bruno W; Dalmasso B; Bellomo SE; Marchiò C; Spagnolo F; Sciallero S; Berrino E; Ghiorzo P
J Transl Med; 2024 May; 22(1):462. PubMed ID: 38750555
[TBL] [Abstract][Full Text] [Related]
6. Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations.
Kuzbari Z; Bandlamudi C; Loveday C; Garrett A; Mehine M; George A; Hanson H; Snape K; Kulkarni A; Allen S; Jezdic S; Ferrandino R; Westphalen CB; Castro E; Rodon J; Mateo J; Burghel GJ; Berger MF; Mandelker D; Turnbull C
Ann Oncol; 2023 Mar; 34(3):215-227. PubMed ID: 36529447
[TBL] [Abstract][Full Text] [Related]
7. Detection of Pathogenic Germline Variants Among Patients With Advanced Colorectal Cancer Undergoing Tumor Genomic Profiling for Precision Medicine.
You YN; Borras E; Chang K; Price BA; Mork M; Chang GJ; Rodriguez-Bigas MA; Bednarski BK; Meric-Bernstam F; Vilar E
Dis Colon Rectum; 2019 Apr; 62(4):429-437. PubMed ID: 30730459
[TBL] [Abstract][Full Text] [Related]
8. Pathogenic Germline Variants in BRCA1/2 and p53 Identified by Real-world Comprehensive Cancer Genome Profiling Tests in Asian Patients.
Satake T; Kondo S; Tanabe N; Mizuno T; Katsuya Y; Sato J; Koyama T; Yoshida T; Hirata M; Yamamoto N
Cancer Res Commun; 2023 Nov; 3(11):2302-2311. PubMed ID: 37916805
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing.
Terraf P; Pareja F; Brown DN; Ceyhan-Birsoy O; Misyura M; Rana S; O'Reilly E; Carlo MI; Aghajanian C; Liu Y; Derakhshan F; Jayakumaran G; Weigelt B; Walsh M; Stadler Z; Offit K; Ladanyi M; Robson M; Zehir A; Reis-Filho JS; Mandelker D
Ann Oncol; 2022 Apr; 33(4):426-433. PubMed ID: 35074424
[TBL] [Abstract][Full Text] [Related]
10. Current status and issues related to secondary findings in the first public insurance covered tumor genomic profiling in Japan: multi-site questionnaire survey.
Minamoto A; Yamada T; Shimada S; Kinoshita I; Aoki Y; Oda K; Ueki A; Higashigawa S; Morikawa M; Sato Y; Hirasawa A; Ogawa M; Kondo T; Yoshioka M; Kanai M; Muto M; Kosugi S
J Hum Genet; 2022 Oct; 67(10):557-563. PubMed ID: 35322199
[TBL] [Abstract][Full Text] [Related]
11. Frequency of actionable germline pathogenic variants identified through tumor next-generation sequencing in a gynecologic cancer cohort.
Karpel H; Manderski E; Pothuri B
Int J Gynecol Cancer; 2023 Jul; 33(7):1044-1050. PubMed ID: 36889816
[TBL] [Abstract][Full Text] [Related]
12. Present status of germline findings in precision medicine for Japanese cancer patients: issues in the current system.
Higashigawa S; Matsubayashi H; Kiyozumi Y; Kado N; Nishimura S; Oishi T; Sugino T; Fushiki K; Shirasu H; Yasui H; Mamesaya N; Fukuzaki N; Kunitomo K; Horiuchi Y; Kenmotsu H; Serizawa M
Jpn J Clin Oncol; 2022 May; 52(6):599-608. PubMed ID: 35411369
[TBL] [Abstract][Full Text] [Related]
13. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol.
Meric-Bernstam F; Brusco L; Daniels M; Wathoo C; Bailey AM; Strong L; Shaw K; Lu K; Qi Y; Zhao H; Lara-Guerra H; Litton J; Arun B; Eterovic AK; Aytac U; Routbort M; Subbiah V; Janku F; Davies MA; Kopetz S; Mendelsohn J; Mills GB; Chen K
Ann Oncol; 2016 May; 27(5):795-800. PubMed ID: 26787237
[TBL] [Abstract][Full Text] [Related]
14. Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study.
Normanno N; De Luca A; Abate RE; Morabito A; Milella M; Tabbò F; Curigliano G; Masini C; Marchetti P; Pruneri G; Guarneri V; Frassineti GL; Fasola G; Adamo V; Daniele B; Berardi R; Feroce F; Maiello E; Pinto C
Eur J Cancer; 2023 Jul; 187():174-184. PubMed ID: 37167765
[TBL] [Abstract][Full Text] [Related]
15. Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company from the Payer Perspective.
Reitsma M; Fox J; Borre PV; Cavanaugh M; Chudnovsky Y; Erlich RL; Gribbin TE; Anhorn R
J Manag Care Spec Pharm; 2019 May; 25(5):601-611. PubMed ID: 30632889
[TBL] [Abstract][Full Text] [Related]
16. Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer.
Berchuck JE; Boiarsky D; Silver R; Sunkara R; McClure HM; Tsai HK; Siegmund S; Tewari AK; Nowak JA; Lindeman NI; Rana HQ; Choudhury AD; Pomerantz MM; Freedman ML; Van Allen EM; Taplin ME
JCO Precis Oncol; 2022 Aug; 6():e2200329. PubMed ID: 36103646
[TBL] [Abstract][Full Text] [Related]
17. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group.
Mandelker D; Donoghue M; Talukdar S; Bandlamudi C; Srinivasan P; Vivek M; Jezdic S; Hanson H; Snape K; Kulkarni A; Hawkes L; Douillard JY; Wallace SE; Rial-Sebbag E; Meric-Bersntam F; George A; Chubb D; Loveday C; Ladanyi M; Berger MF; Taylor BS; Turnbull C
Ann Oncol; 2019 Aug; 30(8):1221-1231. PubMed ID: 31050713
[TBL] [Abstract][Full Text] [Related]
18. Feasibility and Clinical Utility of Reporting Hereditary Cancer Predisposition Pathogenic Variants Identified in Research Germline Sequencing: A Prospective Interventional Study.
Hutchcraft ML; Zhang S; Lin N; Pickarski JC; Belcher EA; Wei S; Bocklage T; Miller RW; Villano JL; Cavnar MJ; Kim J; Arnold SM; Ueland FR; Kolesar JM
JCO Precis Oncol; 2024 Jan; 8():e2300266. PubMed ID: 38295319
[TBL] [Abstract][Full Text] [Related]
19. Concordance Between Genomic Alterations Detected by Tumor and Germline Sequencing: Results from a Tertiary Care Academic Center Molecular Tumor Board.
Green MF; Watson CH; Tait S; He J; Pavlick DC; Frampton G; Riedel J; Plichta JK; Armstrong AJ; Previs RA; Kauff N; Strickler JH; Datto MB; Berchuck A; Menendez CS
Oncologist; 2023 Jan; 28(1):33-39. PubMed ID: 35962742
[TBL] [Abstract][Full Text] [Related]
20. Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer.
Lincoln SE; Nussbaum RL; Kurian AW; Nielsen SM; Das K; Michalski S; Yang S; Ngo N; Blanco A; Esplin ED
JAMA Netw Open; 2020 Oct; 3(10):e2019452. PubMed ID: 33026450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
